EUROAPI announced that it has initiated a pivotal collaboration with SpiroChem. SpiroChem and EUROAPI are joining forces to offer their customers a consolidated CRO-CDMO solution, ensuring that industrialization constraints for small molecules are integrated from the initial step of drug design, thereby speeding up the process. Customers from both companies will benefit from SpiroChem?s cutting-edge expertise and innovative solutions in route scouting and EUROAPI?s industrialization strategy to develop the best synthetic routes directly in line with scale-up feasibility, quality, regulatory, environmental requirements, and economic sustainability.

The agreement will further differentiate both companies? value proposition as their customers will benefit from both SpiroChem?s early-stage premium services and EUROAPI?s development and GMP1 manufacturing capacities and skills.